Nykredit A S Makes New $8.02 Million Investment in Biogen Inc. $BIIB

Key Points

• Nykredit A/S purchased 37,134 Biogen shares in the second quarter, representing an investment of approximately $8.02 million. Institutional investors collectively own 87.93% of Biogen’s stock.
• Biogen reported quarterly EPS of $3.60, exceeding estimates of $2.94, while revenue of $2.74 billion also surpassed expectations and increased 3.4% year over year.
• Analysts maintain a generally positive outlook, with the stock holding a “Moderate Buy” consensus rating and an average price target of $230.14; shares recently traded at $219.07.

Nykredit A S purchased a new stake in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 37,134 shares of the biotechnology company's stock, valued at approximately $8,023,000.

Several other large investors have also made changes to their positions in BIIB. Rothschild Investment LLC raised its holdings in Biogen by 12.3% during the fourth quarter. Rothschild Investment LLC now owns 513 shares of the biotechnology company's stock valued at $90,000 after buying an additional 56 shares in the last quarter. Wedbush Securities Inc. boosted its stake in shares of Biogen by 5.1% during the 2nd quarter. Wedbush Securities Inc. now owns 1,164 shares of the biotechnology company's stock worth $251,000 after acquiring an additional 56 shares in the last quarter. Meeder Advisory Services Inc. increased its holdings in shares of Biogen by 1.2% during the 1st quarter. Meeder Advisory Services Inc. now owns 4,721 shares of the biotechnology company's stock valued at $866,000 after acquiring an additional 57 shares during the last quarter. Kera Capital Partners Inc. increased its holdings in shares of Biogen by 3.5% during the 1st quarter. Kera Capital Partners Inc. now owns 1,723 shares of the biotechnology company's stock valued at $316,000 after acquiring an additional 58 shares during the last quarter. Finally, Parallel Advisors LLC raised its stake in shares of Biogen by 1.5% in the 1st quarter. Parallel Advisors LLC now owns 4,367 shares of the biotechnology company's stock valued at $801,000 after acquiring an additional 65 shares in the last quarter. Institutional investors own 87.93% of the company's stock.

Biogen Trading Up 1.7%

Shares of NASDAQ BIIB opened at $219.07 on Tuesday. The company has a 50-day moving average of $211.20 and a two-hundred day moving average of $198.54. Biogen Inc. has a 1-year low of $135.39 and a 1-year high of $225.80. The company has a current ratio of 1.87, a quick ratio of 1.26 and a debt-to-equity ratio of 0.39. The company has a market cap of $32.37 billion, a PE ratio of 38.77, a P/E/G ratio of 2.38 and a beta of 0.17.

Biogen (NASDAQ:BIIB - Get Free Report) last released its earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.94 by $0.66. The company had revenue of $2.74 billion for the quarter, compared to the consensus estimate of $2.46 billion. Biogen had a net margin of 8.32% and a return on equity of 11.18%. The company's revenue was up 3.4% compared to the same quarter last year. During the same period in the prior year, the company posted $5.47 EPS. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. As a group, equities analysts expect that Biogen Inc. will post 12.41 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on BIIB shares. Canaccord Genuity Group boosted their target price on shares of Biogen from $245.00 to $248.00 and gave the stock a "buy" rating in a research report on Thursday, July 30th. Wolfe Research upgraded Biogen from a "peer perform" rating to an "outperform" rating and set a $300.00 price objective on the stock in a research note on Thursday, August 13th. Stifel Nicolaus set a $242.00 price objective on Biogen in a research report on Thursday, September 10th. Zacks Research upgraded Biogen from a "strong sell" rating to a "hold" rating in a research note on Tuesday, July 28th. Finally, Oppenheimer reaffirmed an "outperform" rating and issued a $300.00 target price on shares of Biogen in a report on Wednesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, thirteen have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $230.14.

About Biogen

Biogen Inc is a biotechnology company focused on discovering, developing and commercializing therapies for neurological and neurodegenerative diseases. Founded in 1978, the company is headquartered in Cambridge, Massachusetts, and serves patients and healthcare providers in markets around the world.

Biogen's portfolio includes treatments for multiple sclerosis, including Tecfidera, Vumerity, Tysabri, Avonex and Plegridy, as well as Spinraza for spinal muscular atrophy, developed in collaboration with Ionis Pharmaceuticals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.